Citius Oncology, Inc. (CTOR)
NASDAQ: CTOR · Real-Time Price · USD
0.982
-0.011 (-1.11%)
Dec 27, 2024, 10:15 AM EST - Market open
Company Description
Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies.
It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma.
The company is headquartered in New York, New York.Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.
Citius Oncology, Inc.
| Country | United States |
| Founded | 2021 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| CEO | Leonard Mazur |
Contact Details
Address: 420 Lexington Avenue, Suite 2446 New York, New York 10170 United States | |
| Phone | 347-627-0058 |
Stock Details
| Ticker Symbol | CTOR |
| Exchange | NASDAQ |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| CIK Code | 0001851484 |
| ISIN Number | US17331Y1091 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Leonard L. Mazur | Chairman, Chief Executive Officer and President |
| Jaime Bartushak | Chief Financial Officer and Treasurer |
| Dr. Myron S. Czuczman M.D. | Chief Medical Officer |
| Myron Z. Holubiak | Secretary and Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 12, 2024 | 8-K | Current Report |
| Nov 6, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Sep 13, 2024 | 8-K | Current Report |
| Sep 5, 2024 | 8-K | Current Report |
| Sep 5, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Aug 26, 2024 | 8-K/A | [Amend] Current report |
| Aug 16, 2024 | 8-K | Current Report |
| Aug 16, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Aug 15, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Aug 13, 2024 | 25-NSE | Filing |